Ignite Creation Date:
2024-05-05 @ 11:04 PM
Last Modification Date:
2024-10-26 @ 10:27 AM
Study NCT ID:
NCT01241591
Status:
COMPLETED
Last Update Posted:
2018-12-26
First Post:
2010-11-12
Brief Title:
A Phase 3 Multi Site Randomized Double Blind Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 3 Multi Site Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of CP-690550 as compared to etanercept and the safety of CP-690550 for treatment of moderate to severe chronic plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None